New cocktail of drugs takes on tough breast cancer

NCT ID NCT06027268

Ongoing Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing a combination of four drugs—trilaciclib, pembrolizumab, gemcitabine, and carboplatin—in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The study aims to see how well the treatment works and how safe it is. Thirty-six participants are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trilaciclib, pembrolizumab, gemcitabine, and carboplatin
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced triple-negative breast cancer, potentially slowing tumor growth.
What could go wrong: This is a small, early-phase trial (36 participants) with no control group, so results may not be definitive. The combination of drugs may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Levine Cancer Institute

Charlotte, North Carolina, 28204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.